West Pharmaceutic.Services Logo
US9553061055
864330
WST

West Pharmaceutic.Services

Loading quotes...

Forecast

The analysts' average price target is €380.53 (+8.20%). The median is €378.36 (+7.58%).

Buy
  14
Hold
  2
Sell
  1

  • West Pharmaceutical Services raises full-year outlook after strong organic revenue

    At the Wells Fargo healthcare conference, West Pharmaceutical Services raised its forecast for 2026 organic revenue growth from 7–9% to 10–11%, supported by organic growth in the second quarter that exceeded expectations by $35 million. HVP components are driving growth and now represent more than half of revenue; Annex-1 projects, biologics and GLP-1 programs offer multi-year opportunities. Margin expansion was improved to around 200–250 basis points for the year, while the West Vantage business is being temporarily weighed down by a cyberattack and the expiration of a CGM contract. West plans roughly $250 million in CAPEX, is focused on HVP investments, remains active in share repurchases and sees further growth potential in the Asia-Pacific region and in generics/biosimilars. » More on de.investing.com


  • West Pharmaceutical hits record high after strong Q2 results and raised full-year guidance

    West Pharmaceutical surprised in the second quarter with adjusted earnings per share of $2.37 (expectation $2.08) and revenue of $872.3 million (expectation $839.75 million, +13.8% year‑on‑year). Management raised the full‑year adjusted EPS guidance to $8.85–9.05, well above the consensus of $8.62. The outlook for the third quarter also beat analysts' expectations, pushing the stock in premarket trading to a new yearly high. » More on de.investing.com


  • West Pharmaceutical completes sale of SmartDose 3.5‑mL system

    West Pharmaceutical has completed the sale and transfer of manufacturing and supply rights and the associated facilities for the SmartDose 3.5‑mL on‑body delivery system. The company will continue development and production of other SmartDose versions, including the SmartDose 10‑mL system designed for larger volumes. West operates 50 sites worldwide, reported net sales of USD 3.07 billion for 2025, and its stock trades near its 52‑week high; analysts point to a high P/E ratio of 48.5. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, West Pharmaceutic.Services has already paid €0.57 in dividends. The last payout was in August.

Financials

In the last quarter, West Pharmaceutic.Services had revenue of €772.05M and net profit of €188.93M
(EUR) September 2026
YoY
Revenue 772.05M 12.65%
Gross profit 306.7M 22.63%
Net profit 188.93M 58.37%
EBITDA 276.86M 49.66%

Fundamentals

Metric Value
Market capitalization
€24.34B
Number of shares
69.66M
52-week high/low
€390.18 - €199.27
Dividend yield
0.21%
Dividends TTM
€0.75
Next dividend
€0.23
Beta
1.13
P/E ratio
43.75
PEG ratio
1.36
P/B ratio
9.31
P/S ratio
8.05

Company profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

Name
West Pharmaceutic.Services
CEO
Michel Lagarde
Headquarters Exton, pa
USA
Website
Sector
Health Care
Industry
Life Sciences Tools & Services
IPO
03/17/1980
Employees 10,800

Ticker symbols

Exchange Symbol
NYSE
WST
Frankfurt
WPS.F
Düsseldorf
WPS.DU
SIX
WPS.SW
München
WPS.MU
London
0ADY.L
🍪

Parqet  uses cookies. Learn more